Skip to Content

Tecartus 0.4 – 2 × 108 cells dispersion for infusion

Licence status
Authorised: 14/12/2020
Active substances
Autologous Peripheral Blood T Cells CD4 and CD8 selected and CD3 and CD28 Activated Transduced with Retroviral Vectir Expressing Anti CD19 CD28/CD3-Zeta Chimeric Antigen Receptor and Cultured
Dosage Form
Dispersion for infusion
Licence number
EU/1/20/1492/001
Licence holder
Kite Pharma EU B.V.

Licence information

ATC code
L01XL06 brexucabtagene autoleucel
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Conditions of Licence
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
14/12/2020